Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER2 Negative Breast Cancer × ribociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 21 Melanoma 4 Sarcoma 2 Liposarcoma 2 Breast Cancer Metastatic 2 Thymus Neoplasms 1 Teratoma 1 Ovarian Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neuroendocrine Tumors 1 Neoplastic Cells, Circulating 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Lymphoma 1 Locoregional Recurrence 1 Leukemia 1 Leiomyosarcoma 1 Hematologic Neoplasms 1 HER2-positive Advanced Breast Cancer 1 HER2 Negative Breast Cancer 1 Glioma 1 Glioblastoma 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Endometrial Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Cystadenocarcinoma, Serous 1 Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies 1 Brain Neoplasms 1

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06953882 2025-07-14

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡